Last reviewed · How we verify
NCT04113330: CYD00082
Surveillance of Suspected Dengue Cases for Access to Care for Subjects Identified as Seronegative or Undetermined Before Receiving CYD Dengue Vaccine in Previous Clinical Studies in Colombia
trial in Dengue Fever in 918 participants. Participants enrolled and being followed up; not accepting new ones.
15 July 2028
Quick facts
| Lead sponsor | Sanofi Pasteur, a Sanofi Company |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 918 |
| Start date | 31 January 2020 |
| Primary completion | 15 July 2028 |
| Estimated completion | 15 July 2028 |
| Sites | 1 location across Colombia |
Conditions studied
- Dengue Fever — all drugs for Dengue Fever →
Sponsor
Sanofi Pasteur, a Sanofi Company — full company profile →
Who can join
Eligibility, any sex, with Dengue Fever. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary objective of the study is to identify any suspected dengue case in subjects that received at least one dose of the CYD dengue vaccine who were classified as seronegative or undetermined at baseline (according to PRNT50 at baseline, or anti-non-structural protein 1 \[NS1\] test Post-dose 3) in the Colombian study sites of CYD15, CYD13, CYD29, CYD64, CYD65 trials in order to allow appropriate access to care until the completion of 10 years after the last CYD Dengue Vaccine received by each participant
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04113330
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Dengue Fever
Currently open trials in the same condition.
- NCT06579755 — A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years) · Phase 3 · recruiting
- NCT07409857 — International Registry of Dengue Infection in Congenital Bleeding Disorders (DengueCBDR) · recruiting
- NCT07047521 — A Study on a New Tetravalent Dengue Vaccine (TDV) Formulation in Healthy Adults · Phase 3 · active not recruiting
- NCT07007585 — Risk Factors for Hospitalization and Transfusion Criteria in Patients With Dengue Virus Infection · recruiting
- NCT06665035 — A Study of 2 Doses of Tetravalent Dengue Vaccine (TDV) in Infants and Toddlers · Phase 3 · recruiting
Other Sanofi Pasteur, a Sanofi Company trials
Trials by the same sponsor.
- NCT07536048 — A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years · not yet recruiting
- NCT07222059 — Phase 3 Single Arm, Open Study on vYF in Adults · Phase 3 · completed
- NCT07013747 — Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne · Phase 1, PHASE2 · recruiting
- NCT06838000 — Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) i · Phase 3 · active not recruiting
- NCT06793826 — Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04113330 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sanofi Pasteur, a Sanofi Company
- Last refreshed: 8 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04113330.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing